NCT04971928View on ClinicalTrials.gov

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions

Hepatitis B

Interventions

DRUG

GSK3228836

GSK3228836 will be administered

Trial Locations (2)

32809

GSK Investigational Site, Orlando

78215

GSK Investigational Site, San Antonio

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY